Does a low EPA and omega-3 balance shift inflammation toward pro-inflammatory eicosanoids?

The balance of fatty acids within cell membranes plays a vital role in regulating both the initiation and resolution of physiological inflammation.

Mechanistic pathways of substrate competition

• Enzymatic competition: Eicosapentaenoic acid (EPA) and arachidonic acid (AA) directly compete as substrates for cyclooxygenase (COX-1/COX-2) and lipoxygenase (LOX) enzymes. The relative ratio of these fatty acids in cell membranes determines which pathway dominates.
• Pro-inflammatory signaling: When the tissue profile is characterized by low EPA and an elevated AA-to-EPA ratio, COX and LOX pathways preferentially metabolize the highly abundant AA. This shifts lipid mediator production toward potent, pro-inflammatory eicosanoids, specifically 2-series prostaglandins (such as PGE2) and 4-series leukotrienes (such as LTB4).
• Impaired resolution: Conversely, low EPA levels deprive the enzymatic machinery of the precursor required to synthesize specialized pro-resolving mediators (SPMs). When EPA is abundant, it is metabolized by COX-2 and 5-LOX into E-series resolvins (such as RvE1 and RvE2). These SPMs actively promote the resolution of inflammation by enhancing macrophage efferocytosis and decreasing neutrophil trafficking.

Clinical implications

• Unresolved inflammation: A high AA-to-EPA ratio biochemically biases cellular signaling toward the propagation of inflammatory states. By limiting the synthesis of EPA-derived resolvins, this cellular imbalance prevents the active termination of inflammatory responses, which can contribute to chronic, unresolved tissue inflammation.

Bottom line

• An elevated AA-to-EPA ratio shifts enzymatic processing away from EPA-derived pro-resolving mediators (RvE1, RvE2) and toward pro-inflammatory AA-derived eicosanoids (PGE2, LTB4), creating a biochemical environment that favors the propagation rather than the resolution of inflammation.